Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 169

Similar articles for PubMed (Select 21572163)

1.

Cognitive effects of atypical antipsychotic medications in patients with Alzheimer's disease: outcomes from CATIE-AD.

Vigen CL, Mack WJ, Keefe RS, Sano M, Sultzer DL, Stroup TS, Dagerman KS, Hsiao JK, Lebowitz BD, Lyketsos CG, Tariot PN, Zheng L, Schneider LS.

Am J Psychiatry. 2011 Aug;168(8):831-9. doi: 10.1176/appi.ajp.2011.08121844. Epub 2011 May 15.

2.

Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE-AD effectiveness trial.

Sultzer DL, Davis SM, Tariot PN, Dagerman KS, Lebowitz BD, Lyketsos CG, Rosenheck RA, Hsiao JK, Lieberman JA, Schneider LS; CATIE-AD Study Group.

Am J Psychiatry. 2008 Jul;165(7):844-54. doi: 10.1176/appi.ajp.2008.07111779. Epub 2008 Jun 2.

3.

Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease.

Schneider LS, Tariot PN, Dagerman KS, Davis SM, Hsiao JK, Ismail MS, Lebowitz BD, Lyketsos CG, Ryan JM, Stroup TS, Sultzer DL, Weintraub D, Lieberman JA; CATIE-AD Study Group.

N Engl J Med. 2006 Oct 12;355(15):1525-38.

6.

Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison.

Keefe RS, Sweeney JA, Gu H, Hamer RM, Perkins DO, McEvoy JP, Lieberman JA.

Am J Psychiatry. 2007 Jul;164(7):1061-71.

PMID:
17606658
7.

Olanzapine does not enhance cognition in non-agitated and non-psychotic patients with mild to moderate Alzheimer's dementia.

Kennedy J, Deberdt W, Siegal A, Micca J, Degenhardt E, Ahl J, Meyers A, Kaiser C, Baker RW.

Int J Geriatr Psychiatry. 2005 Nov;20(11):1020-7.

PMID:
16250069
8.

Metabolic changes associated with second-generation antipsychotic use in Alzheimer's disease patients: the CATIE-AD study.

Zheng L, Mack WJ, Dagerman KS, Hsiao JK, Lebowitz BD, Lyketsos CG, Stroup TS, Sultzer DL, Tariot PN, Vigen C, Schneider LS.

Am J Psychiatry. 2009 May;166(5):583-90. doi: 10.1176/appi.ajp.2008.08081218. Epub 2009 Apr 15.

9.

Atypical antipsychotics for psychosis in adolescents.

Kumar A, Datta SS, Wright SD, Furtado VA, Russell PS.

Cochrane Database Syst Rev. 2013 Oct 15;10:CD009582. doi: 10.1002/14651858.CD009582.pub2. Review.

PMID:
24129841
10.

Efficacy and safety of haloperidol versus atypical antipsychotic medications in the treatment of delirium.

Yoon HJ, Park KM, Choi WJ, Choi SH, Park JY, Kim JJ, Seok JH.

BMC Psychiatry. 2013 Sep 30;13:240. doi: 10.1186/1471-244X-13-240.

11.

Comparison of longer-term safety and effectiveness of 4 atypical antipsychotics in patients over age 40: a trial using equipoise-stratified randomization.

Jin H, Shih PA, Golshan S, Mudaliar S, Henry R, Glorioso DK, Arndt S, Kraemer HC, Jeste DV.

J Clin Psychiatry. 2013 Jan;74(1):10-8. doi: 10.4088/JCP.12m08001. Epub 2012 Nov 27.

12.
13.

Effects of risperidone and quetiapine on cognition in patients with schizophrenia and predominantly negative symptoms.

Riedel M, Spellmann I, Strassnig M, Douhet A, Dehning S, Opgen-Rhein M, Valdevit R, Engel RR, Kleindienst N, Müller N, Möller HJ.

Eur Arch Psychiatry Clin Neurosci. 2007 Sep;257(6):360-70. Epub 2007 Jul 14.

PMID:
17629731
14.

Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study.

Stroup TS, Lieberman JA, McEvoy JP, Swartz MS, Davis SM, Capuano GA, Rosenheck RA, Keefe RS, Miller AL, Belz I, Hsiao JK; CATIE Investigators.

Am J Psychiatry. 2007 Mar;164(3):415-27.

PMID:
17329466
15.

The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease.

Ballard C, Waite J.

Cochrane Database Syst Rev. 2006 Jan 25;(1):CD003476. Review.

PMID:
16437455
16.

Effect of second-generation antipsychotics on caregiver burden in Alzheimer's disease.

Mohamed S, Rosenheck R, Lyketsos CG, Kaczynski R, Sultzer DL, Schneider LS.

J Clin Psychiatry. 2012 Jan;73(1):121-8. doi: 10.4088/JCP.10m06574. Epub 2011 Sep 6.

17.

Atypical antipsychotics for disruptive behaviour disorders in children and youths.

Loy JH, Merry SN, Hetrick SE, Stasiak K.

Cochrane Database Syst Rev. 2012 Sep 12;9:CD008559. doi: 10.1002/14651858.CD008559.pub2. Review.

PMID:
22972123
18.
19.

Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial.

Keefe RS, Bilder RM, Davis SM, Harvey PD, Palmer BW, Gold JM, Meltzer HY, Green MF, Capuano G, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Davis CE, Hsiao JK, Lieberman JA; CATIE Investigators; Neurocognitive Working Group.

Arch Gen Psychiatry. 2007 Jun;64(6):633-47.

PMID:
17548746
20.

Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials.

Schneider LS, Dagerman K, Insel PS.

Am J Geriatr Psychiatry. 2006 Mar;14(3):191-210.

PMID:
16505124
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk